On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience

被引：39
作者：
Chakraborty, Sudipta [1 ]
Vimalnath, K. V. [1 ]
Lohar, Sharad P. [1 ]
Shetty, Priyalata [1 ]
Dash, Ashutosh [1 ]
机构：
[1] Bhabha Atom Res Ctr, Isotope Applicat & Radiopharmaceut Div, Bombay 400085, Maharashtra, India
来源：
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY | 2014年 / 302卷 / 01期
关键词：
Targeted radionuclide therapy; (n; gamma)Lu-177; Target burn-up; Specific activity; INDIGENOUSLY PRODUCED LU-177; DOTA-TATE; TYR(3) OCTREOTATE; RADIOIMMUNOTHERAPY; LU-177-DOTA(0); RADIOTHERAPY; EFFICACY; CANCER; AGENTS;
D O I：
10.1007/s10967-014-3169-z
中图分类号：
O65 [分析化学];
学科分类号：
070302 ; 081704 ;
摘要：
This paper accentuates on the practical aspects and intricate technicalities involved in the large-scale production of Lu-177 with specific activity > 740 GBq mg(-1) following (n,gamma)Lu-177 route in a medium flux (similar to 1.2 x 10(14) n cm(-2) s(-1) thermal neutron) research reactor. The implication of target burn-up on the specific activity of Lu-177 during irradiation was discussed in detail. Lu-177 obtained from this route has been extensively utilized for targeted therapy in patients with neuroendocrine tumor in India. The important details available from our experience, as well as technical know-how, would be of considerable value for institutions planning to pursue Lu-177 production through (n,gamma)Lu-177 route.
引用
收藏
页码：233 / 243
页数：11
相关论文
共 33 条
[1]  
Bakker WH, 2003, J NUCL MED, V44, p320P
[2]   SEPARATION OF CARRIER-FREE LU-177 FROM NEUTRON-IRRADIATED NATURAL YTTERBIUM TARGET [J].
BALASUBRAMANIAN, PS .
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY-ARTICLES, 1994, 185 (02) :305-310
[3]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[4]   Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario [J].
Banerjee, S. ;
Das, T. ;
Chakraborty, S. ;
Venkatesh, M. .
RADIOCHIMICA ACTA, 2012, 100 (02) :115-126
[5]   Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities [J].
Breeman, WAP ;
de Jong, M ;
Visser, TJ ;
Erion, JL ;
Krenning, EP .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (06) :917-+
[6]   Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis [J].
Chakraborty, Sudipta ;
Das, Tapas ;
Sarma, Haladhar Dev ;
Venkatesh, Meera ;
Banerjee, Sharmila .
APPLIED RADIATION AND ISOTOPES, 2008, 66 (09) :1196-1205
[7]   177Lu-EDTMP:: A viable bone pain palliative in skeletal metastasis [J].
Chakraborty, Sudipta ;
Das, Tapas ;
Banerjee, Sharmila ;
Balogh, Lajos ;
Chaudhari, Pradip R. ;
Sarma, Haladhar D. ;
Polyak, Andras ;
Mathe, Domokos ;
Venkatesh, Meera ;
Janoki, Gyozo ;
Pillai, Maroor R. A. .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (02) :202-213
[8]   An electro-amalgamation approach to isolate no-carrier-added 177Lu from neutron irradiated Yb for biomedical applications [J].
Chakravarty, Rubel ;
Das, Tapas ;
Dash, Ashutosh ;
Venkatesh, Meera .
NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (07) :811-820
[9]   Radiometals for Combined Imaging and Therapy [J].
Cutler, Cathy S. ;
Hennkens, Heather M. ;
Sisay, Nebiat ;
Huclier-Markai, Sandrine ;
Jurisson, Silvia S. .
CHEMICAL REVIEWS, 2013, 113 (02) :858-883
[10]   177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India [J].
Danthala, Madhav ;
Kallur, K. G. ;
Prashant, G. R. ;
Rajkumar, K. ;
Rao, M. Raghavendra .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (07) :1319-1326
1234